dence indicates that ET B is normally present in a wide variety of tissues in the adult rat, including many that may be involved in regulation of arterial blood pressure. Among these are the glia and neurons in regions of the brainstem involved in the central control of cardiovascular function (11, 12) , endothelial cells and vascular smooth muscle throughout the body, the atrial and ventricular myocardium, atrioventricular conducting tissue, and coronary vasculature. ET B is also found in multiple endocrine tissues (13) and renal tubules (14) .
Animals with naturally occurring or targeted mutation of ET B exhibit coat color spotting and distal intestinal aganglionosis because ET B plays essential roles in the normal development of epidermal melanocytes and enteric neurons (15) (16) (17) . ET B mutations account for approximately 5% of human Hirschsprung disease (18) (19) (20) . We previously reported that spotting lethal (sl) rats carry a 301-bp deletion in ET B . The deletion results in an abnormal mRNA transcript and completely abrogates functional ET B expression (16) . When homozygous for this deletion (ET B sl/sl ), rats die shortly after birth due to intestinal obstruction (21) . To investigate the roles of ET B in adult physiology, we undertook a tissue-specific transgenic "rescue" of the intestinal phenotype in the (sl) rat. We generated transgenic rats harboring a wild-type rat ET B cDNA whose expression is driven by the human dopamine--hydroxylase (DBH) promoter. This 5.8-kb fragment of the human DBH promoter drives ET B expression in the neural crest-derived enteric nervous system precursors as they colonize the developing gut (22) . Rats carrying this transgene were crossed with the spotting lethal rats to produce individuals that express ET B only under the transcriptional control of the DBH promoter (DBH-ET B ;ET B sl/sl ). The resulting rats exhibit normal enteric nervous system development, live into adulthood, and reproduce normally (23) .
DBH-ET B ;ET B
sl/sl adults rats express ET B in adrenergic tissues (such as the locus ceruleus, adrenal medulla, and sympathetic ganglia). However, these rats lack expression of ET B driven by the endogenous promoter.
Here we report that DBH-ET B ;ET B sl/sl rats are functionally ET B deficient and are a novel single-locus genetic model of severe salt-sensitive hypertension. Our results strongly suggest that DBH-ET B ;ET B sl/sl rats exhibit systemic arterial hypertension as a result of an absence of inhibition of the apical epithelial sodium channel (ENaC) on the renal collecting duct epithelium. This study provides evidence that ET B plays a physiologically important role in regulation sodium excretion by the kidney.
Methods

ET B genotyping by PCR. Our DBH-ET B ;ET B sl/sl and DBH-ET B ;ET B
+/+ rats are albino and not distinguishable by coat color. ET B genotyping is accomplished by PCR on DNA isolated from tail biopsy specimens obtained at 2-3 weeks of age following a previously published protocol (23) . The 3′ primer was designed from sequence within the first intron of ET B . The PCR reaction will not amplify the DBH-ET B transgene, which does not contain this intron sequence. The primers were designed to amplify across the deletion in the spotting lethal ET B . Therefore, the wild-type product is 301 bp longer than the spotting lethal mutant product. Both bands are amplified in a single PCR reaction and viewed on a 1.4% agarose, ethidium bromide stained gel.
DBH-ET B transgene genotyping. We previously published a protocol for transgene identification and quantification (23) . Briefly, we use the technique of dot-blot hybridization of genomic DNA isolated from tail biopsies. The probe is a 2.2-kb SstII fragment from the human DBH promoter cut from the transgene vector.
In situ hybridization. Sectional in situ hybridization for ET B mRNA in adult rat kidneys was performed exactly as described previously (24) . The ET B probe is a 293-bp fragment corresponding to the 3′ end of the first exon isolated by PCR amplification. The probe was labeled with [ 35 S]-UTP (Amersham) using the Maxiscript in vitro translation kit (Ambion Inc., Austin, Texas, USA). The probe does not detectably cross-hybridize with ET A , and it also does not detect the abnormal transcript produced by the ET B sl allele (23) . Femoral artery catheterization. These studies were approved by the Institutional Animal Care Research Advisory Committee at The University of Texas Southwestern Medical Center at Dallas. Catheters were placed in the right femoral artery using standard surgical techniques. For the procedure, rats were anesthetized with ketamine (50 mg/kg) and xylazine (9 mg/kg) by subcutaneous injection. The catheter was exteriorized and secured between the scapulae. The tubing was flushed with 0.1 mL of 500 U/mL heparin saline and occluded with a small piece of fishing line.
Blood pressure measurement. Rats were allowed to recover from catheter placement for 24 hours. The externalized arterial catheter was connected to a previously calibrated blood pressure transducer. The animal was then placed in a high-walled cage with the catheter connection balanced over a lever on a swivel device hanging above the cage. The catheter was flushed with less than 0.1 mL heparin saline, and pulsatile blood pressure was recorded using a MacLab paperless recording system (model 8s; AD Instruments, Milford, Massachusetts, USA). The sampling rate was 400 Hz. Rats with arterial catheters persistently recording narrow pulse pressures (< 20 mmHg) were not further studied. Rats were allowed to acclimate to the measurement conditions for 1 hour. Baseline pressures were obtained in the second hour. Because the animals were freely moving and active, artifacts were frequently introduced into the tracing. The final values used for data analysis represent a continuous 10-minute interval selected on the basis of (a) consistency of tracing and (b) relatively low heart rate. Pharmacologic interventions were made at the end of the baseline hour, and blood pressure monitoring generally continued for an additional hour. All blood pressure measurements/recordings and drug responses in transgenic rats (DBH-ETB;ET B +/+ , DBH-ETB;ET B +/sl , or DBH-ETB;ET B sl/sl ) were done in a genotype-blinded fashion. Blood pressures were measured only in male rats and, except where specifically indicated, all rats were 8-10 weeks old.
Blood sample collection. After blood pressure measurement was complete, blood samples were obtained through the catheter without disturbing the rat. All blood samples were collected between 1500 and 1800 hours.
Measurement of ET-1 concentrations. Plasma was extracted as described elsewhere (25) . Measurement of immunoreactive ET-1 concentrations in plasma were made using a commercially available enzyme linked immunoassay (EIA) kit (Wako Chemicals USA Inc., Richmond, Virginia, USA). All procedures were conducted according to the manufacturer's instructions. The kit also detects ET-2, but not ET-3 or big ET-1.
Plasma renin activity and aldosterone concentration. Plasma renin activity was measured exactly as described previously (26) . Briefly, blood samples were collected into prechilled syringes and rapidly transferred to ice-cold microcentrifuge tubes containing EDTA. Plasma was separated by centrifugation at 4°C and immediately frozen at -80°C. The concentration of active renin was determined by RIA measurement of angiotensin I generation from angiotensinogen. Angiotensin I was measured in samples with and without proteinase treatment. The difference reflects renin activity in the plasma sample (Endocrine Sciences, Calabasas Hills, California, USA). Aldosterone concentration was measured by RIA after solvent extraction (Endocrine Sciences).
Plasma catecholamine and corticosterone concentration.
Plasma epinephrine and norepinephrine concentrations were measured by a commercially available RIA kit (American Laboratory Products Corp., Windham, New Hampshire, USA) following the manufacturer's instructions. Plasma corticosterone was measured by RIA after solvent extraction.
Dietary treatments. Rats were fed either a normal rodent diet (0.8% NaCl), a sodium-deficient diet (0.008% NaCl), or a high-sodium diet (8% NaCl). All diets were purchased from Harlan Teklad Laboratory (Winfield, Iowa, USA). All rats were fed a normal diet until 5 weeks of age. The sodium-deficient or high-sodium diets were introduced at 5 weeks of age and continued for 3 weeks, except where specifically indicated, before blood pressure measurement. The high-sodium diet and sodium-deficient diets were not visually distinguishable. Blood pressure measurements/recordings were made blinded to the type of diet the rat was receiving.
Drug treatments. Where indicated, rats were treated acutely with L-NAME (23 mg/kg) and indomethacin (5 mg/kg), FR139317 (10 mg/kg), or captopril (30 mg/kg). These treatments were given intra-arterially, through the catheter used for blood pressure measurement. These medications were suspended in pH neutral solutions with a dosing volume of 0.5 µL/g. Where indicated, amiloride (3 mg/kg) was given by intraperitoneal injection daily for 3 days before blood pressure measurement. Amiloride was suspended in normal saline, and the dosing volume was 1.5 µL/g. Finally, some rats were given ET-1 (1 nmol/kg) through a femoral venous catheter. The injection volume was 100 µL. For all drug treatments, vehicle injection produced no change in arterial blood pressures.
Statistics. Data were analyzed using InStat or Prism software (Graph-Pad Software Inc., San Diego, California, USA). Comparisons between 2 groups were made using the Student's t test. Three or more groups were compared using 2-way ANOVA. Mean values are reported ± SEM, and P values of less than 0.05 are considered significant. 
Results
DBH-ET
b). Signal in DBH-ET B ;ET B
sl/sl is not significantly increased over background. The probe corresponds to the fragment of the ET B mRNA that is deleted in the spotting lethal ET B mRNA; hence, it will not detect the nonfunctional ET B sl transcript. This probe for ET B mRNA does not cross-detect ET A mRNA (23) .
To show that adult DBH-ET B ;ET B sl/sl rats are functionally ET B deficient, we examined vascular responses to acute ET-1 injection (Figure 2 ). DBH-ET B ;ET B sl/sl rats show a significantly different response to exogenous ET-1 compared with ET B +/+ rats (P < 0.001 by paired t test). Acute injection of ET-1 into wild-type rats produces a transient vasodilatory response followed by a prolonged pressor response. The initial vasodilatory phase is well described as an ET B -mediated response (27) . Although this response, including the hypotensive phase, is clearly demonstrated in DBH-ET B ;ET B +/+ rats after administration of 1 nmol/kg ET-1, it is completely absent in DBH-ET B ;ET B sl/sl rats. Figure 2 shows the response of DBH-ET B ;ET B sl/sl rats fed a high-sodium diet for 3 weeks and treated with amiloride for 3 days before study. Although their baseline blood pressure was lower, their response to acute administration of ET-1 was identical to DBH-ET B ;ET B sl/sl fed a normal diet before study (data not shown).
The DBH-ET B transgene does not affect blood pressure. To show that the rescuing transgene per se has no effect on blood pressure, we measured blood pressure in nontrans- rats fed a sodium-deficient diet (0.008% NaCl) or a high-sodium diet (8% NaCl). +/+ rats on a low-sodium diet exhibited a circulating ET-1 level of 2.1 ± 1.8 pg/mL (n = 4) and DBH-ET B ;ET B +/+ rats on a high-sodium diet exhibited a circulating ET-1 level of 4.4 ± 1.4 pg/mL (n = 6). The plasma ET-1 levels in DBH-ET B ;ET B sl/sl rats fed a sodium-deficient diet was 13.2 ± 2.8 pg/mL (n = 11), significantly elevated compared with DBH-ET B ;ET B +/+ rats fed a sodium-deficient diet (P = 0.04). DBH-ET B ;ET B sl/sl rats fed a high-sodium diet exhibited a plasma ET-1 level significantly elevated (23.9 ± 4.2 pg/mL; n = 8) compared with both DBH-ET B ;ET B +/+ rats fed a high-sodium diet (P = 0.002) and DBH-ET B ;ET B sl/sl rats fed a sodiumdeficient diet (P = 0.04). However, ET B genotype, but not diet, was a significant independent variable affecting plasma ET-1 level (P < 0.001), and there was no interaction of diet and genotype by 2-way ANOVA. To investigate the extent to which activation of ET A contributes to the hypertension observed in ET B -deficient rats, we acutely treated DBH-ET B ;ET B +/+ and DBH-ET B ;ET B sl/sl rats fed a high-sodium diet with 10 mg/kg FR139317, a selective ET A antagonist. Figure 5b shows that DBH-ET B ;ET B sl/sl rats have a significantly increased response (-15 ± 5 mmHg in ∆MAP) to FR139317 com- (110 ± 3 mmHg) rats. All rats were maintained on a high-sodium diet (8% NaCl) for at least 3 weeks before measurement and were 8-to 10-week-old males. No difference in pulse rate was found (data not shown 
mmHg) rats. Systolic and diastolic pressures in DBH-ET B ;ET B
sl/sl rats were increased. No significant difference in pulse rate was observed (data not shown). All rats were fed a normal rodent chow (0.8% NaCl) and were 8-to 10-week-old males. Blood pressure was measured in acclimated, conscious, unrestrained rats via a femoral artery catheter 24 hours after surgery.
pared with DBH-ET B ;ET B
+/+ rats (-3 ± 2 mmHg in MAP; P = 0.01). The effect of acute ET A blockade was relatively small and did not normalize MAP in salt-fed
DBH-ET B ;ET B
sl/sl rats. 
Salt-fed DBH-ET B ;ET B sl/sl rats exhibit appropriate downregulation of the renin-angiotensin-aldosterone system. We investigated whether increased activity of the reninangiotensin-aldosterone system (RAS) is involved in the salt-sensitive hypertension observed in DBH-ET B ;ET
mmHg). DBH-ET B ;ET B
+/+ rats showed no response to amiloride treatment. All animals were maintained on the designated diet for 3 weeks before study and were 8-to 10-week old males.
ET B; ET B
sl/sl rats are ET B deficient in the kidney (Figure 1 ). In addition, we demonstrate that DBH-ET B ;ET B sl/sl rats are functionally ET B deficient in their response to exogenous intravenous ET-1 (Figure 2) . The complete absence of the transient vasodepressor response to exogenous ET-1 administration in DBH-ET B ;ET B sl/sl rats confirms that they lack functional endothelial ET B .
Importantly, we did not detect a physiologically relevant effect of the DBH-ET B transgene. DBH-ET B ;ET B +/+ rats were indistinguishable from nontransgenic ET B +/+ rats in arterial blood pressure, pulse rate, blood chemistries, arterial blood gases, circulating renin activity, and plasma aldosterone, corticosterone, and catecholamines concentrations (Figure 3a and Table 1) .
Hypertension in DBH-ET B ;ET B sl/sl rats is due to inappropriate activity of the ENaC. Although DBH-ET B ;ET B
sl/sl rats exhibit severe hypertension when fed a high-sodium diet, they exhibit a normal arterial blood pressure when placed on a sodium-deficient diet. That is, the hypertension is salt dependent. We found no evidence that hypertension in DBH-ET B ;ET B sl/sl rats results from inappropriate regulation of RAS. Renin activity and aldosterone levels were appropriately low in salt-fed DBH-ET B ;ET B sl/sl rats, and they were not significantly different from those found in salt-fed DBH-ET B ;ET B +/+ rats. Further, DBH-ET B ;ET B sl/sl rats showed a normal response to acute treatment with captopril. However, salt-fed DBH-ET B ;ET B sl/sl rats respond dramatically to amiloride at doses that specifically block the activity of ENaC (Figure 4 ). In contrast, we detected no response to amiloride in salt-fed DBH-ET B ;ET B +/+ rats (Figure 4b ). This is consistent with previous studies that show that amiloride has no effect on ENaC activity in normal animals on a high-sodium diet (29) . DBH-ET B ;ET B sl/sl rats, therefore, exhibit inappropriate activity of ENaC while consuming a high-sodium diet. Although the RAS is an important physiological regulator of ENaC activity, it appears that in DBH-ET B ;ET B sl/sl rats, ENaC activity is high in the absence of elevated RAS activity. Hypertension and abnormal ENaC activity occur in DBH-ET B ;ET B sl/sl rats in the face of appropriately very low renin activity and aldosterone levels. The amiloride-sensitive ENaC plays a key role in sodium transport in the kidney. It constitutes the final limiting step for sodium reabsorption in the epithelium of the distal nephron. Inappropriate ENaC activity leads to increased renal sodium reabsorption and hypertension. This is demonstrated in humans with gain-of-function ENaC mutations producing Liddle's syndrome.
We examined other proposed ET B -mediated depressor mechanisms to evaluate their role in hypertension in the DBH-ET B ;ET B sl/sl rat. Because ET B activation leads to increased production of NO and prostacyclin in the endothelium, we looked for evidence that the hypertension observed in DBH-ET B ;ET B sl/sl rats was the result of reduced production of these vasoactive compounds. If the hypertension is the result of decreased NO and prostacyclin production, DBH-ET B ;ET B sl/sl rats might exhibit decreased acute responses to L-NAME and indomethacin. However, we found no difference between DBH-ET B ;ET B sl/sl and DBH-ET B ;ET B +/+ rats in their hypertensive response to acute treatment with L-NAME and indomethacin. These findings suggest that the basal activity of NOS and cyclooxygenase are not changed in DBH-ET B ;ET B sl/sl rats and that it is unlikely that the hypertension observed is due to decreased basal production of NO and prostacyclin. Because endothelial ET B is thought to play a role as a clearance receptor for circulation ET-1, and because decreased clearance of circulating ET-1 may lead to increased activation of ET A and vasoconstriction, we examined both circulating ET-1 levels and responses to ET A blockade in our rats. DBH-ET B ;ET B sl/sl rats exhibit increased circulating ET-1 (Figure 5a) . However, the circulating ET-1 level in DBH-ET B ;ET B sl/sl rats is significantly elevated both in rats fed a sodium-deficient diet and those fed a high-sodium diet. Although the level of dietary sodium did not detectably alter the plasma ET-1 level in the rats overall as judged by 2-way ANOVA (P = 0.08), it may affect circulating ET-1 levels in DBH-ET B ;ET B sl/sl rats (P = 0.04 by Student's t test). Possible explanations for this observation include: (a) ET B activation normally suppresses ET-1 production in the presence of high sodium intake; (b) ET B in its role as a clearance receptor obscures increased production of ET-1 in response to high sodium intake; or (c) hypertension in DBH-ET B ;ET B sl/sl rats on a high-sodium diet leads to a secondary increase in ET-1 production. The present study does not enable us to distinguish these possibilities.
We also found that rats. It may be that these rats are, as in hypertensive humans and several other animal models of hypertension, more responsive to ET A blockade than are normotensive rats, perhaps owing to secondary vascular damage.
We cannot exclude the possibility that increased activation renal tubule ET A modulates ENaC activity in DBH-ET B ;ET B sl/sl rats, although we believe this is unlikely for several reasons. First, renal tubules express predominantly ET B . Second, functional studies implicate ET B in mediating most ET-1 effects in the renal tubule (14) . ET-1 primarily inhibits sodium and water reabsorption by the cortical collecting tubule through activation of ET B on the basolateral membrane. Urinary sodium is increased in response to ET-1 in both the isolated perfused rat kidney and rats infused with subpressor doses of ET-1 (30) . It is likely that at physiological levels, ET-1 acts through ET B to inhibit renal sodium reabsorption (31) . Gallego and colleagues (1996) , in patch-clamp studies using the A6 distal nephron cell line, found dosedependent and receptor-dependent effects of basolateral ET-1 on sodium transport. They found that low-dose ET-1 inhibits the ENaC through ET B activation, whereas high-dose (pressor dose) ET-1 increased ENaC sodium transport through ET A activation. However, while many studies implicate ET B in mediating diuresis and natriuresis at the renal tubule, the role of ET A in modulating intact renal tubular function remains obscure.
Finally, while the hypertension in salt-fed DBH-ET B ;ET B sl/sl rats is severe, it is not progressive. This suggests that although inappropriately increased ENaC activity continues, the rats are able eventually to compensate for this increased activity and balance sodium excretion with sodium intake. The mechanisms by which this is accomplished require further study.
Other models of ET B deficiency. Ohuchi et al. recently reported hypertension in mice with naturally occurring decreased expression of ET B (33) . These mice express approximately one-eighth the normal level of ET B . They found that the pressor response to acute treatment with BQ-788, an ET B -specific antagonist, could be blocked by pretreatment with indomethacin. They suggest that ET elicits depressor effects through ET B under basal conditions, in part through tonic production of prostacyclin. In the present study, did not address this issue directly. We compared the response of DBH- (15, 17, 31, 33) . However, the response of the endothelin system within the kidney to alterations in sodium and water balance is controversial. Michel and colleagues examined plasma and urinary ET-1 levels in response to water deprivation and sodium loading in rats. They found that urinary ET-1 was significantly decreased in response to water deprivation. In addition, they detected an increase in renal ET-1 binding, although they did not investigate which receptor type was involved (35) . They also found no change in rat urinary ET-1 (or renal ET-1 binding) in response to salt loading with 0.9% NaCl drinking water (35) . Firth and colleagues found no change in renal expression of ET-1 in rats in response to salt restriction or diuretic treatment (36) . More recently, Melo and colleagues (37) using an RIA on extracted tissue protein, detected an average 46% increase in renal ET-1 in wild-type mice fed an 8% NaCl diet compared with mice fed a sodium-deficient diet for 1 week. In contrast, Morita and colleagues (38) using an EIA on extracted tissue protein, detected an average 50% decrease in renal ET-1 in wild-type mice fed an 8% NaCl diet compared with mice fed a normal diet for 4 weeks. ET-1 extracted from kidneys may reflect renal production, but it may also reflect ET-1 produced elsewhere and bound in the kidney. More direct measurements of local ET-1 production in the kidney may help resolve these controversies.
Conclusions. Our data indicate that DBH-ET B ;ET B
sl/sl rats are functionally ET B deficient and, as a result, exhibit extreme salt-sensitive hypertension. The hypertension is salt dependent, i.e., the animals are normotensive on a sodium-deficient diet. Maintenance of the hypertension does not involve increased activity of the RAS, increased circulating catecholamines, or decreased production of the endothelial-derived vasodilators, NO and prostacyclin. Increased activity of the distal tubule ENaC occurs in ET B -deficient rats fed a high-salt diet, as evidenced by the dramatic response of these rats to specific ENaC inhibition. Taken together, these results strongly suggest that DBH-ET B ;ET B sl/sl rats exhibit systemic arterial hypertension as a result of abnormal high activity of ENaC on the renal collecting duct epithelium under high oral sodium intake. This study of the DBH-ET B ;ET B sl/sl rat provides the first evidence for a physiologically important role of ET B in renal sodium handling in the whole animal. Our results suggests that in the distal nephron, the endothelin system (via epithelial ET B ) acts as a counterbalance to the RAS in regulation of the collecting duct ENaC, i.e., the activation of epithelial ET B downregulates the ENaC under high salt intake (promoting natriuresis). Further, while ET B activation has many described effects, its dominant role in the intact rat is in regulating ENaC activity. In this manner, the endothelin system contributes substantially to the kidney's ability to control sodium excretion, and therefore, plays an important role in fluid-volume regulation.
